comparemela.com

Latest Breaking News On - Ashleigh barreto - Page 4 : comparemela.com

Viracta Therapeutics Chief Scientific Officer, Dr Ayman Elguindy, Elected to the Governing Board of the International Association for Research on Epstein-Barr Virus and Associated Diseases

/PRNewswire/ Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the.

United statesIvor roystonAyman elguindyAshleigh barretoYale universityInternational association for research on epstein barr virusHead of investor relations corporate communicationsNational cancer instituteInternational symposiumPrnewswire viracta therapeutics incAssociation governing boardDepartment of pathologyYale university school of medicineDepartment of pediatricsViracta therapeutics incAmerican cancer society

Viracta Therapeutics Appoints Jane Chung, R Ph , to its Board of Directors

/PRNewswire/ Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the.

New yorkUnited statesColumbia universitySutro biopharmaJane chungAshleigh barretoRogerj pomerantzHead of investor relations corporate communicationsAstrazeneca pharmaceuticalsPrnewswire viracta therapeutics incGenentech incEffectiveness for onyx pharmaceuticals incJohn universityViracta therapeutics incChief commercial officerGeneral manager

Viracta Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates

Continued progress of NAVAL-1, the pivotal trial of Nana-val for the treatment of Epstein-Barr virus-positive (EBV+) lymphoma; update on the initi.

United statesSan diegoIvor roystonA dimitrios colevasAyman elguindyEzra cohenAshleigh barretoSilicon valley bankUniversity of californiaInternational association for research on epstein barr virusHead of investor relations corporate communicationsAmerican society of clinical oncologyInternational symposiumPrnewswire viracta therapeutics incScience history instituteScience history institute biotechnology heritage award

Viracta Therapeutics President and Chief Executive Officer Dr Ivor Royston Receives the Science History Institute s Biotechnology Heritage Award

/PRNewswire/ Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that its.

San diegoUnited statesIvor roystonAshleigh barretoHead of investor relations corporate communicationsInternational conventionScience history institute biotechnology heritage awardScience history instituteBiotechnology innovation organizationScientific history instituteViracta therapeutics incViracta therapeuticsChief executive officerBiotechnology heritageBiotechnology heritage awardScience history

Viracta Therapeutics President and Chief Executive Officer Dr Ivor Royston Receives the Science History Institute s Biotechnology Heritage Award

/PRNewswire/ Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that its.

San diegoUnited statesIvor roystonAshleigh barretoHead of investor relations corporate communicationsInternational conventionScience history institute biotechnology heritage awardScience history instituteBiotechnology innovation organizationScientific history instituteViracta therapeutics incViracta therapeuticsChief executive officerBiotechnology heritageBiotechnology heritage awardScience history

vimarsana © 2020. All Rights Reserved.